tetano
Editor, Senior Moderator
Inflamm Bowel Dis
. 2022 Apr 9;izac071.
doi: 10.1093/ibd/izac071. Online ahead of print.
The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy
Dalin Li[SUP] 1 [/SUP], Alexander Xu[SUP] 2 [/SUP], Emebet Mengesha[SUP] 1 [/SUP], Rebecca Elyanow[SUP] 3 [/SUP], Rachel M Gittelman[SUP] 3 [/SUP], Heidi Chapman[SUP] 3 [/SUP], John C Prostko[SUP] 4 [/SUP], Edwin C Frias[SUP] 4 [/SUP], James L Stewart[SUP] 4 [/SUP], Valeriya Pozdnyakova[SUP] 1 [/SUP], Philip Debbas[SUP] 1 [/SUP], Angela Mujukian[SUP] 1 [/SUP], Arash A Horizon[SUP] 5 [/SUP], Noah Merin[SUP] 2 [/SUP], Sandy Joung[SUP] 6 [/SUP], Gregory J Botwin[SUP] 1 [/SUP], Kimia Sobhani[SUP] 7 [/SUP], Jane C Figueiredo[SUP] 2 [/SUP], Susan Cheng[SUP] 6 [/SUP], Ian M Kaplan[SUP] 2 [/SUP], Dermot P B McGovern[SUP] 1 [/SUP], Akil Merchant[SUP] 2 [/SUP], Gil Y Melmed[SUP] 1 [/SUP], Jonathan Braun[SUP] 1 7 [/SUP]
Affiliations
No abstract availableKeywords: IBD biologic therapy; SARS-CoV-2; T-cell response; TCR clonal; antibody response; inflammatory bowel disease; vaccination.
Plain Language Summary
T-cell and antibody responses to severe acute respiratory syndrome coronavirus 2 vaccination in inflammatory bowel disease patients are poorly correlated. T-cell responses are preserved by most biologic therapies, but augmented by anti-tumor necrosis factor (anti-TNF) treatment. While anti-TNF therapy blunts the antibody response, cellular immunity after vaccination is robust.
. 2022 Apr 9;izac071.
doi: 10.1093/ibd/izac071. Online ahead of print.
The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy
Dalin Li[SUP] 1 [/SUP], Alexander Xu[SUP] 2 [/SUP], Emebet Mengesha[SUP] 1 [/SUP], Rebecca Elyanow[SUP] 3 [/SUP], Rachel M Gittelman[SUP] 3 [/SUP], Heidi Chapman[SUP] 3 [/SUP], John C Prostko[SUP] 4 [/SUP], Edwin C Frias[SUP] 4 [/SUP], James L Stewart[SUP] 4 [/SUP], Valeriya Pozdnyakova[SUP] 1 [/SUP], Philip Debbas[SUP] 1 [/SUP], Angela Mujukian[SUP] 1 [/SUP], Arash A Horizon[SUP] 5 [/SUP], Noah Merin[SUP] 2 [/SUP], Sandy Joung[SUP] 6 [/SUP], Gregory J Botwin[SUP] 1 [/SUP], Kimia Sobhani[SUP] 7 [/SUP], Jane C Figueiredo[SUP] 2 [/SUP], Susan Cheng[SUP] 6 [/SUP], Ian M Kaplan[SUP] 2 [/SUP], Dermot P B McGovern[SUP] 1 [/SUP], Akil Merchant[SUP] 2 [/SUP], Gil Y Melmed[SUP] 1 [/SUP], Jonathan Braun[SUP] 1 7 [/SUP]
Affiliations
- PMID: 35397000
- DOI: 10.1093/ibd/izac071
No abstract availableKeywords: IBD biologic therapy; SARS-CoV-2; T-cell response; TCR clonal; antibody response; inflammatory bowel disease; vaccination.
Plain Language Summary
T-cell and antibody responses to severe acute respiratory syndrome coronavirus 2 vaccination in inflammatory bowel disease patients are poorly correlated. T-cell responses are preserved by most biologic therapies, but augmented by anti-tumor necrosis factor (anti-TNF) treatment. While anti-TNF therapy blunts the antibody response, cellular immunity after vaccination is robust.